

**REGION III IPP LAB TECHNOLOGY OVER TIME 1993 – 2006**

PROJ. AREA	SITE TYPE	1993	1994	1995	1996	1997	1998	1999
BALT. Hopkins	STD/ FP/ Schools		ROCHE PCR  Roche PCR	ROCHE PCR  Roche PCR	ROCHE PCR  Abbott LCR	ROCHE PCR  Abbott LCR	ROCHE PCR  Abbott LCR	ROCHE PCR  Abbott LCR
DE	STD/ FP	Sanofi EIA	Syva EIA w/DFA conf. of pos. and 50% NGZ (11/94 to present)	Syva EIA w/DFA conf. of pos. and 50% NGZ	Syva EIA w/DFA conf. of pos. and 50% NGZ	Syva EIA w/DFA conf. of pos. and 50% NGZ	Syva EIA w/DFA conf. of pos. and 50% NGZ	Syva EIA w/DFA conf. of pos. and 50% NGZ (8/98LCR on urine,males)
MD	STD/ FP	Syva EIA w/ DFA conf of pos.	Syva EIA w/ DFA conf. or Gen Probe Pace 2 w/ PCA conf. of pos. (4/94)	(Syva EIA w/ DFA conf. of pos.) or (Gen Probe Pace 2 w/ PCA conf. of pos and PCR in 30% NGZ (1/95) then 50% NGZ (8/95)	(Syva EIA w/LCR conf. of pos. and LCR in 70% NGZ) or (GenProbe Pace 2 w/ LCR conf. of pos and LCR in the 70% NGZ 5/97 stop PCR, DFA conf of EIA pos. & PCA conf. of GenProbe pos.	(Syva EIA w/ LCR conf. of pos. and LCR in 70% NGZ or (GenProbe Pace 2 w/ LCR conf. of pos. and LCR in 70% NGZ) 5/97 stop PCR, DFA conf of EIA pos. & PCA conf. of GenProbe pos.	Syva EIA w/ LCR conf. of pos. and LCR in 70% NGZ or (GenProbe Pace 2 w/ LCR conf. of pos. and LCR in 70% NGZ) 7/98 stop GenProbe and began LCR urine for juvenile justice	Syva EIA w/LCR conf. of pos and LCR in 50% NGZ – 70% NGZ  Urine LCR
PA	FP	Sanofi EIA	Sanofi EIA or Sanofi DFA	Sanofi DFA (all sites 5/95)	Syva DFA (4/96)	Gen Probe w/TMA in 50% NGZ (7/97)	Gen Probe w/TMA in 50% NGZ	10/18/99 FPC switch LCR; 11/99 Western Cncl switch to LCR . Remainder of state uses GenProbe
PHILA.	STD	GenProbe	GenProbe	GenProbe w/PCA Conf. of pos. and PCA in 50%-70% NGZ	GenProbe Combi w/PCA Conf. of pos. and PCA in 50-70% NGZ (10/96)	Gen Probe Combi w/ PCA conf. of pos. and PCA in 50-70% NGZ & TMA Study	GenProbe Amp Ct w/ repeat of all positives (initiated 5/98, full conversion 6/98)	GenProbe Amp Ct w/ repeat of all positives
	FP				LCR (11/96)	LCR	LCR	LCR
VA	STD/ FP	Ortho EIA w/ Blocking ± 10% Gray zone. Syva EIA w/ Blocking on all pos. (Fall93)	Syva EIA w/ Blocking on all pos.	Syva EIA w/ Blocking on all pos.	EIA (10/96-10/97) LCR (10/97)	LCR (10/97-Present)	LCR  3/98 LCR Urine Screening added	LCR  (pooling of cervical specimens began)
D.C.	STD		GenProbe Pace 2	GenProbe Pace 2	GenProbe Pace 2	GenProbe Pace 2	GenProbe Pace 2	GenProbe Pace 2 w/ PCA conf. began 5/99
	FP					DFA	DFA	GenProbe Pace 2 w/ PCA conf. began 5/99
W.VA.	STD/ FP	Chlamydiazyme EIA	Syva EIA w/ blocking on all pos. (7/94) and blocking in 25% NGZ (9/94)	Syva EIA w blocking on all pos. and blocking in 50% NGZ	Syva EIA w/DFA conf. of low pos and NGZ (11/96)	EIA w/DFA conf. of low pos. and NGZ or GenProbe Pace 2 w/ PCA conf. of pos. and PCA in 50% NGZ (10/97)	GenProbe Pace 2C w/PCA conf. of pos. and PCA in 50%NGZ	GenProbe Pace 2C w/ PCA conf of pos. and PCA in 50% NGZ

**REGION III IPP LAB TECHNOLOGY OVER TIME 1993 – 2006**

PROJ. AREA	SITE TYPE	2000	2001	2002	2003	2004	2005	2006
BALT.	STD/ FP	ROCHE PCR	ROCHE PCR	ROCHE PCR	ROCHE PCR	Roche PCR	Roche PCR	Roche PCR
HOPKINS	Schools	Abbott LCR	Abbott LCR	BD ProbeTec	BD ProbeTec	BD ProbeTec	BD Probe Tec	BD Probe Tec
DE	STD/ FP	Syva EIA w/DFA conf. of pos. and 50% NGZ (LCR on urine,male)	Syva EIA w/DFA conf. of pos. and 50% NGZ (LCR on urine,male)	Syva EIA w/DFA conf. of pos. and 50% NGZ <b>7/2002 change from LCR to BD on urine, male</b> Non state facilities using EIA	BD ProbeTec (urines and state FP/STD clinics – swabs) Syva EIA w/DFA confirm 50% NGZ – non state clinic swabs	BD ProbeTec (urines and state FP/STD clinics – swabs) Syva EIA w/DFA confirm 50% NGZ – non state clinic swabs, <b>July 2004 all BD ProbeTec</b>	All BD ProbeTec	All BD ProbeTec
MD	STD/ FP	Syva EIA w/LCR conf. of pos and LCR in 50-70% NGZ (Urine by LCR)	Syva EIA w/LCR conf. of pos. & LCR in 50-70% NGZ (Urine by LCR)	Syva EIA w.LCR conf. of pos.& LCR in 50-70% NGZ (Urine by LCR) 8/02 switch LCR to BD	Syva EIA with ProbeTec conf. of pos. ProbeTec in 50%NGZ - 70% NGZ. Urine by BD ProbeTec.	Syva EIA with ProbeTec conf. of pos. ProbeTec in 50%NGZ - 70% NGZ. Urine by BD ProbeTec.	Syva EIA weith BD ProbeTec conf. in 50-80%NGZ. Urine by BDProbeTec repeat all positives with same test	Syva EIA weith BD ProbeTec conf. in 50-80%NGZ. Urine by BDProbeTec repeat all positives with same test
PA	FP/STD (STD always BD Probetec)	FPC uses LCR; Western Council mostly LCR; Remainder of state uses GenProbe	FPC uses LCR; Western Council mostly LCR; Remainder of state uses GenProbe <b>Entire state changed to BD's SDA tech July 1, 2001</b>	BD ProbeTec <b>FPC changed to APTIMA November 2002</b>	BD ProbeTec FPC APTIMA Dec. through June 2003, <b>FPC changed to BD in July 2003</b>	BD ProbeTec	BD ProbeTec	BD ProbeTec
PHILA.	STD	GenProbe Amp Ct w/ repeat of all positives	GenProbe Amp Ct w/ repeat of all positives <b>Aptima July 2001</b>	APTIMA	APTIMA	APTIMA	APTIMA	APTIMA
	FP	LCR	LCR	LCR, <b>changed to Aptima in November 2002</b>	APTIMA	APTIMA	APTIMA	APTIMA
VA	STD/ FP	LCR 3/2000 pooling of all DCLS specimens	LCR – all pooling	At DCLS LCR – all pooling EIA for other labs <b>October 2002 changed to BD ProbeTec with pooling</b>	BD ProbeTec w/ Pooling	BD ProbeTec w/ Pooling	BD ProbeTec w/pooling	BD ProbeTec w/pooling
D.C.	STD	GenProbe Pace 2 w/ PCA conf.	GenProbe Pace 2 w/ PCA conf.	GenProbe Pace 2 w/PCA conf.	GenProbe Pace 2 w/PCA conf.	GenProbe Pace 2 w/PCA conf.	GenProbe Pace2 w/PCA conf.	GenProbe Pace2 w/PCA conf.
	FP	GenProbe Pace 2 w/ PCA conf.	GenProbe Pace 2 w/ PCA conf.	GenProbe Pace 2 w/PCA conf.	GenProbe Pace 2 w/PCA conf.	GenProbe Pace 2 w/PCA conf.	GenProbe Pace2 w/PCA conf.	GenProbe Pace2 w/PCA conf.
W.VA.	STD/ FP	GenProbe Pace 2C with PCA conf. of pos. & PCA in 50% NGZ	GenProbe Pace 2C w/ PCA conf. of pos. & PCA in 50% NGZ	GenProbe Pace 2C w/PCA conf. of pos. & PCA in 50% NGZ <b>6/2002 Aptima Urine</b>	GenProbe Pace 2C w/PCA conf. of pos. & PCA in 50% NGZ <b>6/2002 Aptima Urine</b>	GenProbe Pace 2C w/PCA conf. of pos. & PCA in 50% NGZ APTIMA urine	GenProbe Pace 2C w/PCA conf. of pos. & PCA in 50% NGZ APTIMA urine	GenProbe Pace 2C w/PCA conf. of pos. & PCA in 50% NGZ APTIMA urine

**REGION III IPP LAB TECHNOLOGY OVER TIME 1993 – 2006**